ArticleActa biomaterialia2021
Efficient Differentiation of Human Induced Pluripotent Stem Cells into Endothelial Cells under Xenogeneic-free Conditions for Vascular Tissue Engineering.
Article in Acta biomaterialia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 32 citations in OpenAlex.
- Ex vivo endothelialized cECM-enriched core-shell fibrous vascular graft promotes rapid regenerative remodeling in vivo.Bioactive materials · 2026Article
- Synthetic and Tissue-Engineered Vascular Grafts: Current Status, Emerging Technologies, and Clinical Prospects.Reviews in cardiovascular medicine · 2025Review
- ETV2 Overexpression Promotes Efficient Differentiation of Pluripotent Stem Cells to Endothelial Cells.Biotechnology and bioengineering · 2025Article
- Fully biologic endothelialized-tissue-engineered vascular conduits provide antithrombotic function and graft patency.Cell stem cell · 2025Article
- Stem-Cell-Based Small-Diameter Blood Vessels with 3D Printing.Small science · 2024Article
- Photo-Crosslinked Pro-Angiogenic Hydrogel Dressing for Wound Healing.International journal of molecular sciences · 2024Article
- Sources and applications of endothelial seed cells: a review.Stem cell research & therapy · 2024Review
- Advancements in preclinical human-relevant modeling of pulmonary vasculature on-chip.European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2024Review
- Advances and Applications of Lung Organoids in the Research on Acute Respiratory Distress Syndrome (ARDS).Journal of clinical medicine · 2024Review
- Biological Materials for Tissue-Engineered Vascular Grafts: Overview of Recent Advancements.Biomolecules · 2023Review
- Breakthrough in large-scale production of iPSCs-derived exosomes to promote clinical applications.Frontiers in bioengineering and biotechnology · 2023Article
- Blood vessel remodeling in late stage of vascular network reconstruction is essential for peripheral nerve regeneration.Bioengineering & translational medicine · 2022Article
- Functional Characterization of Human Induced Pluripotent Stem Cell-Derived Endothelial Cells.International journal of molecular sciences · 2022Article
- Interplay between mechanics and signalling in regulating cell fate.Nature reviews. Molecular cell biology · 2022Review
- Endothelial and hematopoietic hPSCs differentiation via a hematoendothelial progenitor.Stem cell research & therapy · 2022Article
- Review
- Article
- Review
- Human iPS Cell-derived Tissue Engineered Vascular Graft: Recent Advances and Future Directions.Stem cell reviews and reports · 2021Review
- Vascular Tissue Engineering: Challenges and Requirements for an Ideal Large Scale Blood Vessel.Frontiers in bioengineering and biotechnology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
Abstract
Tissue engineered vascular grafts (TEVGs) represent a promising therapeutic option for emergency vascular intervention. Although the application of small-diameter TEVGs using patient-specific primary endothelial cells (ECs) to prevent thrombosis and occlusion prior to implantation could be hindered by the long time course required for in vitro endothelialization, human induced pluripotent stem cells (hiPSCs) provide a robust source to derive immunocompatible ECs (hiPSC-ECs) for immediate TEVG endothelialization. To achieve clinical application, hiPSC-ECs should be derived under culture conditions without the use of animal-derived reagents (xenogeneic-free conditions), to avoid unwanted host immune responses from xenogeneic reagents. However, a completely xenogeneic-free method of hiPSC-EC generation has not previously been established. Herein, we substituted animal-derived reagents used in a standard method of xenogeneic hiPSC-EC differentiation with functional counterparts of human origin. As a result, we generated xenogeneic-free hiPSC-ECs (XF-hiPSC-ECs) with similar marker expression and function to those of human primary ECs. Furthermore, XF-hiPSC-ECs functionally responded to shear stress with typical cell alignment and gene expression. Finally, we successfully endothelialized decellularized human vessels with XF-hiPSC-ECs in a dynamic bioreactor system. In conclusion, we developed xenogeneic-free conditions for generating functional hiPSC-ECs suitable for vascular tissue engineering, which will further move TEVG therapy toward clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.